Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Richard Torbett
Associate feature: A Manifesto for Health and Growth
Every advance in medicines – from vaccines to treatments that extend life – depends on strong partnerships between government, the NHS, academia and industry. This “triple helix” drives Scotland’s life sciences growth, contributing over £1.7 billion to the economy and supporting 15,000 high-value jobs.
Clinical trial hubs to open as part of £400m public-private investment
PA Wire Up to 18 new clinical trial hubs will open across the UK as part of a £400 million public-private investment aimed at fast-tracking new medicines. Experts said the move will benefit patients by making the NHS a more attractive place to undertake research. Health Secretary Wes Streeting also hailed the investment as a “significant vote of confidence in the UK” that will transform it into an “epicentre of health research, supporting an NHS fit for the future”.
Re: High drug prices are not justified by industry’s spending on research and development
Dear Editor, We note with interest the article by Angelis et al., arguing that high drug prices are not justified by industry’s spending on research and development (R&D). While we appreciate the call for more medically valuable and affordable innovations, there are areas where the evidence does not support the assertions in the paper. The article argues that prices do not reflect the R&D investment associated with new products.
Hunt 'disappointed' by drugs giant's low tax move
But he said the government would not consider tax cuts funded by borrowing."But the only tax cuts we won't consider are ones that are funded by borrowing because they're not a real tax cut.Mr Hunt has warned it is unlikely there will be any room for "significant" tax cuts in the Budget in March.The firm's chief executive said it had wanted to build the site in north-west England, but the "discouraging" tax rate meant it chose Dublin instead.
How COVID-19 is evolving the R&D landscape
By Richard Torbett, Chief executive, Association of the British Pharmaceutical Industry As the world waits for a pandemic exit strategy, we know that the organisations researching and developing medicines and vaccines are our best hope for beating coronavirus. As new vaccines become a reality, we are seeing scientific partnerships that were forged in the spring leading us out of the pandemic. And among them is a home-grown UK vaccine from AstraZeneca and Oxford University.
All eyes have turned to global science in this pandemic - but where are we in terms of treatment?
The expression is usually uttered in relation to vaccination programmes: PA In the current global COVID-19 pandemic, many eyes are on the response of global scientists and companies. Across the life sciences industry there are thousands of scientists turning their attention and expertise to COVID-19, prioritising research and development of diagnostics, treatments, health technologies and vaccines.
NHS spending on branded drugs has been capped
Richard Torbett, executive director of commercial policy Association of the British Pharmaceutical Industry, London SW1E 6QT, UK rtorbett{at}abpi.org.uk Naci and Dixon discuss the new voluntary scheme for branded drugs.1 But the claim that NHS spending on drugs has been rising sharply is not entirely accurate. It is true in some areas, such as in specialised medicines where the increase is because of a wave of new treatment options. But overall, NHS spending on branded drugs has been capped …
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Richard
Contact Richard, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack